Last updated: 2026-09-06 22:46:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rocket Pharmaceuticals, Inc. (RCKT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3,87, with a market capitalization of $423,73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,53 to $5,45. This page covers its latest market performance, valuation, price trends and company information.
$423,73M | |
$3,77 | |
$67,48 | |
$2,19 | |
$3,79 | |
789,89K | |
-- | |
-- | |
$5,45 | |
$2,53 | |
-- | |
-- |
Rocket Pharmaceuticals, Inc. (RCKT) last closed at $3,79 as of 2026-09-04 23:31:00, unchanged from the previous close of $3,79.
During the latest regular trading session, RCKT traded between $2,19 and $67,48, with a volume of 789,89K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Rocket Pharmaceuticals, Inc. (RCKT) moved from $3,77 to $3,87, representing a gain of 2,65% ($0,10).
The stock traded between $3,73 and $3,88 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1,48 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 45,9%
RCKT is currently trading at $3,87, placing it 45,9% of the way from its 52-week low of $2,53 to its 52-week high of $5,45. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 202 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rocket Pharmaceuticals, Inc. (RCKT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.